Standaard Boekhandel gebruikt cookies en gelijkaardige technologieën om de website goed te laten werken en je een betere surfervaring te bezorgen.
Hieronder kan je kiezen welke cookies je wilt inschakelen:
Technische en functionele cookies
Deze cookies zijn essentieel om de website goed te laten functioneren, en laten je toe om bijvoorbeeld in te loggen. Je kan deze cookies niet uitschakelen.
Analytische cookies
Deze cookies verzamelen anonieme informatie over het gebruik van onze website. Op die manier kunnen we de website beter afstemmen op de behoeften van de gebruikers.
Marketingcookies
Deze cookies delen je gedrag op onze website met externe partijen, zodat je op externe platformen relevantere advertenties van Standaard Boekhandel te zien krijgt.
Je kan maximaal 250 producten tegelijk aan je winkelmandje toevoegen. Verwijdere enkele producten uit je winkelmandje, of splits je bestelling op in meerdere bestellingen.
This text provides a clinical framework for the diagnosis and management of more than seventy potential neurological complications that may occur in the HIV infected patient. The clinical framework is designed to be "user friendly" so that even the most inexperienced clinician should be able to arrive at the correct diagnosis. The neurological complications of HIV disease have considerably changed in the last decade. Not only have more opportunistic conditions been described but other complications arising from antiretroviral drugs such as lipodystrophy and accelerated atherosclerosis have become problematic. Moreover, the pattern of complications has altered. Diseases such as cerebral toxoplasmosis, AIDS dementia complex and primary central nervous system lymphoma are now becoming uncommon to rare while peripheral neuropathy is becoming increasingly common. In line with these changes, there have been very significant advances in the therapy of HIV disease in general and in neurological complications in particular. Patients with AIDS dementia complex now have a variety of antiretroviral and adjuvant drugs available to them in contrast to the situation only five years ago where therapy was confined to two antiretroviral drugs at best.